Johnson & Johnson (JNJ) posted 6% operational sales growth and lifted its 2026 outlook, but a roughly $7 billion talc litigation resolution dragged GAAP EPS down to $0.09.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results